New Mission, New Website coming soon! Learn more now.

Equities logo
Close this search box.

Johnson & Johnson Announces Lead Vaccine Candidate for COVID-19, Partnership With US Government

J&J and BARDA have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing.

Source: Johnson & Johnson

(Reuters) – Johnson & Johnson said on Monday it made a deal with the U.S. government to create enough manufacturing capacity for more than one billion doses of a vaccine it is testing to fight the new coronavirus that has killed more than 34,000 people around the world.

Johnson & Johnson said that it had selected its own lead vaccine candidate and would start human testing of its experimental coronavirus vaccine by September, with an eye on having it ready for emergency use in early 2021, the drugmaker said on Monday.

J&J said that the first batches of a vaccine could be available under an emergency use authorization in early 2021, far quicker than the typical 18 month period that it takes for vaccines to be tested, approved and then manufactured.

J&J also committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority (BARDA) to co-fund vaccine research, expanding a previous collaboration. BARDA is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services,

The new coronavirus has infected people in most countries around the world. The United States now has the most cases globally and many of them are in New York, where hospitals are reporting a scarcity of resources to treat the COVID-19 respiratory disease it causes.

A patient was dosed with Moderna Inc’s vaccine in an early-stage trial earlier this month, making it the front-runner in the race to develop a viable vaccine.

J&J said in January it had begun working on a possible vaccine for the coronavirus, using the same technologies used to make its experimental Ebola vaccine.

Reporting by Manas Mishra in Bengaluru and Caroline Humer in New York; Editing by Saumyadeb Chakrabarty and Nick Zieminski.


Source: Reuters